Eiko Nakamaru-Ogiso, PhD

Adjunct Professor of Pediatrics (Human Genetics)
Research Laboratory Director, Mitochondrial Medicine Frontier Program, Children's Hospital of Philadelphia
Department: Pediatrics
Contact information
Children’s Hospital of Philadelphia
Mitochondrial Medicine Frontier Program
Abramson Research Building (ARC) 1002A
3615 Civic Center Blvd
Philadelphia, PA 19104
Mitochondrial Medicine Frontier Program
Abramson Research Building (ARC) 1002A
3615 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-590-6815
Fax: 215-590-0583
Lab: 215-590-6815
Fax: 215-590-0583
Lab: 215-590-6815
Email:
ogisoe@email.chop.edu
ogisoe@email.chop.edu
Publications
Links
Search PubMed for articles
Research Laboratory Director, Mitochondrial Medicine Frontier Program
Search PubMed for articles
Research Laboratory Director, Mitochondrial Medicine Frontier Program
Education:
B.S. (Biochemistry & Nutrition)
University of Tokyo, 1988.
M.S. (Biochemistry & Nutrition)
University of Tokyo, 1990.
Ph.D. (Biochemistry & Neuroscience)
University of Tokyo, 1998.
Permanent linkB.S. (Biochemistry & Nutrition)
University of Tokyo, 1988.
M.S. (Biochemistry & Nutrition)
University of Tokyo, 1990.
Ph.D. (Biochemistry & Neuroscience)
University of Tokyo, 1998.
Description of Research Expertise
Description of Research ExpertiseThe Ogiso's lab has been studying studying structure and function of bacterial/mitochondrial complex I, which is the entry enzyme of the respiratory chain. Complex I plays a central role in cellular aerobic energy metabolism. Therefore, complex I dysfunctions lead to a remarkably wide range of human diseases including heart failure, type 2 diabetes, and neuronal degenerative diseases such as Parkinson's Disease. Currently, we are tackling one of the most challenging fundamental questions in bioenergetics: How is electron transfer is linked to vectorial H+ translocation in complex I?
We are also interested in how to rescue complex I dysfunction. The most crucial and unique function of complex I is NADH oxidation. Impaired NADH oxidation in mitochondria leads to lactic acidosis, high NADH/NAD+ ratio, increased reactive oxygen species (ROS), and eventually, apoptosis. One effective strategy is a complementation of dysfunctional complex I by fixing altered NADH/NAD+ balance to protect cells from excessive ROS generation. We are investigating the NAD+ metabolism in cells and animals, and searching for strategies to modulate NADH/NAD+ levels metabolically.